BIOMAT Database Logo BIOMAT Database Logo

[Dual biochemical modulation therapy using 5-FU, leucovorin and cisplatin on human rectal carcinoma xenografts in nude mouse]. 1996

M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Dept. of Surgery, Showa University School of Medicine, Japan.

This study examined a combined treatment for colorectal carcinoma, the dual biochemical modulation therapy, consisting of 5-FU, Leucovorin (LV) and Cisplatin (CDDP). We compared its anti-tumor effects with other treatments: 5-FU alone, CDDP alone and 5-FU with LV. Primary diffuse infiltrated colorectal carcinoma is well known for its biological malignancy and its lack of response to chemotherapy. We used SRM cells from a cell line of carcinoma of the rectum, and subcutaneously injected them into nude mice. The anti-tumor effects were estimated from the growth rate, inhibition rate and thymidylate synthetase inhibition rates in the tumor tissue. Results indicated that even if the concentration of 5-FU and LV were reduced by half, these combined with CDDP were more effective than other therapies. Dual biochemical modulation therapy is particularly promising because the reduction of the dosages would reduce the side effects while still serving as an excellent anti-tumor therapy.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
5-FU/leucovorin: biochemical modulation that works?
April 1987, Oncology (Williston Park, N.Y.),
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
[Modulation by 1-leucovorin of 5-fluorouracil antitumor activity on human gastric carcinoma xenograft in nude mouse: preliminary report].
June 1993, Nihon Geka Gakkai zasshi,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Folic acid instead of leucovorin for 5-FU modulation?
January 1988, Oncology (Williston Park, N.Y.),
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
August 2002, Annals of oncology : official journal of the European Society for Medical Oncology,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
January 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
UFT: biochemical modulation for 5-fluorouracil (5-FU).
April 1997, Chinese medical journal,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
January 2005, World journal of gastroenterology,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
March 1992, International journal of cancer,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.
January 1997, International journal of radiation oncology, biology, physics,
M Shibusawa, and M Takata, and G Kamiyama, and N Yokoyama, and K Nakao, and H Yoshizawa, and H Choh, and N Yasuda, and Y Tsunoda, and A Tsunoda, and M Kusano
[Biochemical modulation of 5-FU with interferon].
July 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!